Compare Moderna, Inc. (MRNA) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Teradyne, Inc. — how do they compare? Moderna, Inc. trades at $59.72 (market cap $23.60B), while Teradyne, Inc. trades at $372.22 (market cap $52.25B). The key difference: Teradyne, Inc. is far larger — about 2.2× Moderna, Inc.'s market cap, and Teradyne, Inc. pays a 0.16% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | TER | |
|---|---|---|
Market Cap | $23.60B | $52.25B |
Sector | Health | Technology |
52-Week High | $81.80 | $483.84 |
52-Week Low | $22.36 | $90.15 |
Enterprise Value | $19.70B | $52.08B |
Dividend Yield | — | 0.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Teradyne (TER) trades at $374.15, up 16.07% in 24 hours, with strong quarterly earnings beats and robust AI-driven semiconductor testing demand. The stock shows bearish technical signals but maintains solid fundamentals with 22.55% net income margin and 28.75% ROE. Recent institutional activity includes Amova Asset Management reducing its position by 49.5% in Q1 2026 while maintaining bullish analyst consensus.
TER presents compelling growth potential from AI infrastructure expansion but faces valuation concerns with a 61.92 P/E ratio. The upcoming Q2 2026 earnings report on July 28, 2026, will be crucial for validating the AI-driven growth narrative. Risks include competitive pressures and market volatility, though analyst consensus targets $459.60 suggest 23% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
